TY - JOUR
T1 - Embracing the gut microbiota
T2 - The new frontier for inflammatory and infectious diseases
AU - Van Den Elsen, Lieke W.J.
AU - Poyntz, Hazel C.
AU - Weyrich, Laura S.
AU - Young, Wayne
AU - Forbes-Blom, Elizabeth E.
N1 - Funding Information:
We would like to thank Anna Mooney for her contribution to the review. The contributing authors are supported by the Health Research Council (EFB), the Ministry of Business, Innovation and Employment (LvdE, HCP, WY and EFB) and LSW holds an Australian Research Council DECRA Fellowship (DE150101574).
Publisher Copyright:
© The Author(s) 2017.
PY - 2017
Y1 - 2017
N2 - The gut microbiota provides essential signals for the development and appropriate function of the immune system. Through this critical contribution to immune fitness, the gut microbiota has a key role in health and disease. Recent advances in the technological applications to study microbial communities and their functions have contributed to a rapid increase in host–microbiota research. Although it still remains difficult to define a so-called ‘normal’ or ‘healthy’ microbial composition, alterations in the gut microbiota have been shown to influence the susceptibility of the host to different diseases. Current translational research combined with recent technological and computational advances have enabled in-depth study of the link between microbial composition and immune function, addressing the interplay between the gut microbiota and immune responses. As such, beneficial modulation of the gut microbiota is a promising clinical target for many prevalent diseases including inflammatory bowel disease, metabolic abnormalities such as obesity, reduced insulin sensitivity and low-grade inflammation, allergy and protective immunity against infections.
AB - The gut microbiota provides essential signals for the development and appropriate function of the immune system. Through this critical contribution to immune fitness, the gut microbiota has a key role in health and disease. Recent advances in the technological applications to study microbial communities and their functions have contributed to a rapid increase in host–microbiota research. Although it still remains difficult to define a so-called ‘normal’ or ‘healthy’ microbial composition, alterations in the gut microbiota have been shown to influence the susceptibility of the host to different diseases. Current translational research combined with recent technological and computational advances have enabled in-depth study of the link between microbial composition and immune function, addressing the interplay between the gut microbiota and immune responses. As such, beneficial modulation of the gut microbiota is a promising clinical target for many prevalent diseases including inflammatory bowel disease, metabolic abnormalities such as obesity, reduced insulin sensitivity and low-grade inflammation, allergy and protective immunity against infections.
UR - http://www.scopus.com/inward/record.url?scp=85020099196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020099196&partnerID=8YFLogxK
U2 - 10.1038/cti.2016.91
DO - 10.1038/cti.2016.91
M3 - Article
AN - SCOPUS:85020099196
SN - 2050-0068
VL - 6
JO - Clinical and Translational Immunology
JF - Clinical and Translational Immunology
IS - 1
M1 - e125
ER -